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background, in 18.9% nodular variant with normoechogenic 
background, in 11.7%—micronodulations and in 3.9%—dif-
fuse hypoechogenic background. Eight cases of PTC were 
diagnosed in nodular variant of AIT with normoechogenic 
irregular background.
Conclusion Patients with AIT and nodular variant with 
normoechogenic irregular background of the thyroid gland 
on US scans are in the risk group of developing PTC and 
should be followed up with regular neck US assessment.
Keywords Autoimmune thyroiditis · Normoechogenic 
thyroid background · Normoechogenic thyroid 
parenchyma · Papillary thyroid carcinoma · aTPO · aTG
Introduction
The prevalence of chronic autoimmune thyroiditis (AIT) has 
been assessed as 0.3–2% in children and 4–9.6% in adoles-
cents and is rising [1, 2]. The childhood prevalence of AIT 
peaks in early to mid-puberty, with a female preponderance 
of 2:1 [3]. Presentation is rare under the age of 3 years, but 
few cases have been described in infancy [4]. AIT is consid-
ered to be a premalignant lesion, with an increased preva-
lence in papillary thyroid cancer [5–7].
Papillary thyroid carcinoma (PTC) accounts for 90% 
or more of all childhood differentiated thyroid carcinoma 
(DTC) cases [8]. The prevalence of PTC is rising in the last 
years partly due to more frequent ultrasound (US) assess-
ments and US controlled fine needle aspiration biopsy 
(FNAB) of small nodules of the thyroid gland. The incidence 
of thyroid nodules in children and adolescents is 1–18% [9]. 
The risk of thyroid cancer in children operated due to nod-
ular goiter is significantly higher than in adults (~25% of 
children operated) [8].
Abstract 
Background The prevalence of autoimmune thyroiditis 
(AIT) and papillary thyroid carcinoma (PTC) is rising in 
children and adolescents, and the coincidence of AIT and 
PTC is as high as 6.3–43%.
Objective To investigate the ultrasound manifestation of 
AIT in relation to PTC development in paediatric patients.
Patients 179 paediatric patients (133 females), mean (SD) 
age: 13.9 (3.03) years diagnosed with AIT and referred for 
ultrasound evaluation. Eight patients were diagnosed with 
PTC (6 females).
Methods Retrospective analysis of thyroid ultrasound 
scans of patients diagnosed with AIT. Thyroid and auto-
immune status was assessed based on TSH, fT4, fT3 and 
increased aTPO and/or aTG and/or TRAB levels. In patients 
with PTC, total thyroidectomy was performed.
Results Analysis of thyroid US scans revealed that the fol-
lowing five ultrasound variants of AIT were observed in 
179 patients: the most common in 35.2%—diffuse thyroidi-
tis with hypoechogenic background and normoechogenic 
parenchyma, in 30.2%—diffuse thyroiditis with irregular 
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In the last years, there is an increase of coincidence of 
AIT and PTC in children and adolescents. A coincidence of 
AIT and PTC is ranging between 6.3 and 43%, depending 
on the patients selection [10–12]. Oh et al. [13] presented 
that in patients with PTC, the prevalence of chronic lym-
phocytic thyroiditis increased fourfold in men and twofold 
in women between 1999 and 2008. In pediatric patients 
with PTC, Niedziela et al. [14] found that the prevalence of 
chronic lymphocytic thyroiditis increased tenfold between 
1996–2000 and 2001–2015 years.
According to the current paediatric guidelines neck US 
in children with autoimmune thyroid disease should be 
performed at least every 12 months [8, 15]. Knowing how 
different ultrasound pictures of the thyroid gland in AIT 
patients are observed, the question then arises if PTC can 
be associated with certain type of autoimmune thyroiditis 
variant and whether US evaluation of patients with AIT can 
help in selecting a risk group.
The aim of the present study is a trial to classify US thy-
roid scans in AIT patients and to assess characteristic fea-
tures of thyroid presentation in patients with PTC and AIT.
Subjects and methods
Subjects
The study included 179 paediatric patients (133 females, 46 
males; female-to-male ratio: 2.9:1) diagnosed with AIT and 
referred for ultrasound evaluation in the Out-Patient Endo-
crine Department between years 2015 and 2016. The mean 
age of the patients was 13.9 years (range 5–18 years). Eight 
patients were diagnosed with papillary thyroid carcinoma (6 
females and 2 males, mean age, range 15.3 [11–18] years).
Methods
Retrospective analysis of medical records and thyroid US 
scans of 179 patients diagnosed with AIT between 2015 and 
2016 in the major tertiary paediatric endocrinology center 
was performed.
The analyzed data were as follows: age at diagnosis, gen-
der, thyroid status (euthyroid, hypothyroid, hyperthyroid), 
autoantibodies levels (thyroperoxidase, aTPO; thyroglobu-
line, aTG; and TSH receptor, TRabs, antibodies) and US 
features of the AIT. Autoimmune thyroid disease (AITD) 
was diagnosed based on clinical (presence of goiter, firm 
consistency of the thyroid gland) and hormonal (TSH, fT4, 
fT3 levels) parameters as well as typical features of chronic 
autoimmune thyroiditis on thyroid ultrasound scans and 
increased aTPO, and/or aTG and/or TRab levels. Compen-
sated (or subclinical) hypothyroidism was diagnosed if TSH 
was above the upper normal range (TSH n: 0.4–4.0 uIU/ml) 
and fT4 close to low normal range (fT4 n: 10–25 pmol/l). 
Overt hypothyroidism was diagnosed if TSH was above 
the upper normal range and fT4 was below the low normal 
range. Overt hyperthyroidism was diagnosed if TSH was 
suppressed and fT4 and fT3 above the upper normal range 
(fT3 n: 3.8–6.8 pmol/l). AIT was diagnosed in euthyroid 
patients with an increased aTPO and/or aTG and/or TRab 
antibody levels and typical features of chronic autoimmune 
thyroiditis on thyroid ultrasound scans.
Ultrasound thyroid evaluation
US of the thyroid gland was performed in the Out-Patient 
Endocrine Department of the University Children Hospital 
by one board US certified endocrinologist with 17 years of 
experience in pediatric thyroid imaging and intervention 
(fine needle aspiration biopsy). Thyroid US was performed 
using a high-resolution Voluson 730, GE Medical System 
with an 8- to 12-MHz linear transducer. The US examina-
tion was performed in the longitudinal and axial planes. 
Scans indicating background parenchymal echogenicity 
were reviewed retrospectively. Normal thyroid parenchyma 
(normoechogenic background) was defined as demonstrat-
ing homogenous echogenicity and relative hyperechogenic-
ity compared with the adjacent sternohyoid, sternothyroid, 
omohyoid and sternocleidomastoid muscles. The abnor-
mal parenchymal features of the thyroid gland, including 
irregular echotexture, micronodularity, and diffuse or focal 
hypoechogenic lesions and nodules on gray-scale US, were 
evaluated. FNAB was performed in 34 patients with a nod-
ule found on US.
Statistical analysis
To compare the two groups, the two-sided Mann–Whitney U 
test and ANOVA tests were used. For comparison of multi-
ple groups, ANOVA Kruskal–Wallis test was used. The level 
of significance was set at p < 0.05. Calculations were per-
formed using the STATISTICA 10.0 PL software (Poland).
Results
Analysis of the thyroid ultrasound scans from the last 2 years 
revealed that the following five ultrasound variants of auto-
immune thyroiditis were observed in the study group: the 
most common in 35.2% (63/179)—diffuse thyroiditis with 
hypoechogenic background and normoechogenic paren-
chyma (Fig. 1a, b), in 30.2%(54/179)—diffuse thyroiditis 
with irregular background (Fig. 1c, d), in 18.9% (34/179) 
nodular variant with normoechogenic irregular background 
(Figs. 2a–f, 3a–d), in 11.7% (21/179)—micronodulations 
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(Fig. 4a, b), and in 3.9% (7/179)—diffuse hypoechogenic 
background (Fig. 4c, d; Table 1).
In patients with nodular variant of AIT with normoe-
chogenic irregular background goiter was found in 24/34 
patients (70.6%). In this variant of AIT, the mean nodule 
size was 6.4 mm (2–26 mm). Uninodularity was found in 
30 patients (88.2%) and multinodularity in 4 (n = 11.8%). 
FNAB was performed in all patients. In 26/34 patients, 
FNAB result was assessed as benign (Bethesda II) [16]. 
PTC was diagnosed after FNAB fulfilling Bethesda V 
or VI criteria in 8/34 patients (8/34-23.5%, 8/179-4.5%; 
Table 2) [16]. In patients with PTC, the mean tumor size 
was 13.3 mm (6–26 mm) (Table 2). In 5 patients with PTC, 
malignant nodules were hypoechogenic (Figs. 2a, d, 3a, c, 
d), in 2 patients isoechogenic with hypoechogenic “halo” 
(Fig. 2c, e, f) and in 1 patient with diffuse sclerosing PTC 
variant, tiny disseminated hyperechogenic septae and multi-
ple microcalcifications in the whole thyroid gland were seen 
Fig. 1  a, b Diffuse thyroiditis 
with hypoechogenic background 
and normoechogenic paren-
chyma, c, d diffuse thyroiditis 
with irregular background
Fig. 2  Nodular AIT variants with normoechogenic irregular back-
ground with PTC development. a, b Axial planes of thyroid gland of 
17-year-old girl; c longitudinal plane of thyroid gland of 11-year-old 
boy; d an axial plane of thyroid gland of 18-year-old girl; e, f axial 
and longitudinal planes of thyroid gland of 17-year-old girl
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on US imaging (Fig. 3e, f). In all PTC cases, the echogenic-
ity of thyroid parenchyma was increased when related to the 
adjacent sternothyroid, sternohyoid, sternocleidomastoid or 
omohyoid muscles (Figs. 2, 3). In patients with PTC total 
thyroidectomy with lateral and central lymph nodes, histo-
pathological verification was performed. After the surgery, 
the clinical outcome in all patients was good and all patients 
are in remission.
TSH range in different ultrasound classes is presented in 
Table 1. Analysis of the thyroid status revealed that in our 
group, 47.5% (85/179) patients were hypothyroid [54.1% 
(46/85) with compensated hypothyroidism and 45.9% 
(39/85)—with an overt hypothyroidism], 36.8% (66/179) 
were euthyroid and 15.6% (28/179) were hyperthyroid at 
diagnosis (Table 1).
In diffuse thyroiditis with hypoechogenic background 
and normoechogenic parenchyma variant 69.8% (44/63) 
patients were hypothyroid at diagnosis (59.1% with 
an overt and 40.9% with compensated hypothyroid-
ism), 17.5% (11/63) were euthyroid and 12.7% (8/63) 
Fig. 3  Nodular AIT variants with normoechogenic irregular back-
ground with PTC development. a, b Axial planes of thyroid gland 
of 18-year girl; c axial and longitudinal plane of thyroid gland of 
14.5-year-old girl; d an axial plane of thyroid gland of 14-year-old 
girl; e, f axial and longitudinal planes of thyroid gland of 13-year-old 
boy with diffuse sclerosing variant of PTC
Fig. 4  a, b AIT variant with 
micronodulations; c, d AIT 
variant with diffuse hypoecho-
genic background
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hyperthyroid. Significantly higher aTPO and aTG levels 
were observed in diffuse thyroiditis with hypoechogenic 
background and normoechogenic parenchyma variant 
when compared with other AIT variants and aTPO level 
was also significantly higher than in PTC group.
In diffuse thyroiditis with irregular background, 37% 
(20/54) were hypothyroid (55% with compensated and 
45% with an overt hypothyroidism), 35.2% (19/54) euthy-
roid and 27.8% (15/54) hyperthyroid.
In nodular variant and normoechogenic irregular back-
ground 52.9% (18/34) were euthyroid, 35% (12/34) hypo-
thyroid (83.3% with compensated and 16.7% with an overt 
hypothyroidism) and 11.8% (4/34) hyperthyroid. Analy-
sis of patients with nodular variant and normoechogenic 
irregular background revealed that PTC was diagnosed in 
27.8% (5/18) of euthyroid, 25% (1/4) of hyperthyroid, and 
16.6% (2/12) of hypothyroid patients in this group (all 
with compensated hypothyroidism). On the other hand, 
thyroid status analysis of patients with coexistence of AIT 
and PTC revealed that 62.5% (5/8) PTC patients were 
euthyroid, 25% (2/8) with compensated hypothyroidism 
and 1 patient was hyperthyroid. The patient with PTC and 
thyrotoxicosis was diagnosed at the age of 16.8 years. The 
cause of referral to the endocrine center was goiter and 
TSH < 0.02 uIU/ml (n: 0.4–4.0), raised fT3-13.4 pmol/l 
(n: 3–8.1) and fT4-31.6 pmol/l (n: 10–25). TRab level was 
5.2 IU/ml (N < 1.0) at diagnosis and 1.0 IU/ml a year later 
at the time of PTC diagnosis. This patient was treated with 
decreasing doses of antithyroid drug (thiamasole) until the 
surgery. The nodule was 13 mm in size, hypoechogenic 
with microcalcifications, irregular border and increased 
vascularisation (Fig. 2d; Table 2).
One of the patients with papillary thyroid carcinoma 
had a diffuse sclerosing variant of PTC with very high 
unmeasurable aTPO (>9000 IU/ml) and aTG (>8000 IU/
ml) levels. After excluding this patient from the PTC 
group, the mean levels of autoantibodies were as follows: 
aTPO was 1362.2 IU/ml [range 2081.9–5911.2 IU/ml) and 
aTG-129.4 IU/ml (range 127.9–300 IU/ml). After the sur-
gery in all PTC patients aTg level was negative.
In micronodulation variant 52.4% (11/21) were euthy-
roid, 42.8% (9/21) hypothyroid (77.8% with compensated 
and 22.2% with an overt hypothyroidism) and 4.8% (1/21) 
hyperthyroid.
Seven patients (3.9%) with positive but relatively low 
levels of aTPO and aTG levels with diffuse hypoechogenic 
background on US scans were euthyroid and during fur-
ther monitoring 3 of them presented a normalization of US 
echogenicity and aTPO and aTG levels (data not shown). 
We suspect that this variant corresponds to a transient thy-
roiditis or to an early phase of AIT.
Discussion
The analysis of US features seen on the thyroid scans 
revealed that the following five US variants of autoimmune 
thyroiditis were observed in our group of 179 paediatric 
patients: the most common in 35.2% diffuse thyroiditis 
with hypoechogenic background and normoechogenic 
parenchyma, in 30.2% diffuse thyroiditis with irregular 
background, in 18.9% nodular variant with normoecho-
genic irregular background, in 11.7% micronodulations, 
and in 3.9% diffuse hypoechogenic background. These 
ultrasound autoimmune thyroiditis features were already 
described in previous studies [9, 17–20] but present classi-
fication is, to our knowledge, relatively novel in paediatric 
patients.
In our study group, we have found papillary thyroid carci-
noma in 8 patients (8/179 cases) that constituted 4.5% of the 
whole group. All eight cases of papillary thyroid carcinoma 
were diagnosed in nodular variant of AIT with normoecho-
genic irregular background. 23.5% of patients (8/34 cases) 
with this variant of AIT developed PTC. In 5 patients with 
PTC malignant nodules were hypoechogenic, in 2 patients 
isoechogenic with hypoechogenic “halo” and in 1 patient 
with diffuse sclerosing PTC variant, tiny disseminated 
hyperechogenic septae and multiple microcalcifications 
fulfilling whole thyroid gland were seen on US imaging. 
In all cases, the echogenicity of thyroid parenchyma was 
increased when related to the adjacent sternothyroid, ster-
nohyoid, sternocleidomastoid or omohyoid muscles. Our 
results are supported by previous work presenting nodular 
form of Hashimoto’s thyroiditis within a sonographic back-
ground of normal thyroid parenchyma [19]. Usually on US 
scans in AIT, hyperechoic nodules are more likely to be 
benign, whereas hypoechoic nodules are more likely to be 
malignant [19]. In our study, however, two cases of PTC 
were isoechogenic with hypoechogenic “halo”.
Papillary thyroid carcinoma (PTC) accounts for 90% or 
more of all childhood DTC cases [8]. According to the data 
of the Polish National Cancer Registry from 2003 to 2013, 
new cases of thyroid cancer in patients below 19 years of 
age constitute 2.3% of all thyroid cancers diagnosed (535 of 
22,817 cases in general population) [8] and constitute every 
second solid neoplasm in girls (following tumors of the cen-
tral nervous system) and every eighth solid neoplasm in boys 
[8]. In the last decade, the incidence of thyroid cancer has 
been increasing at a 6.5% annual rate, making it the fastest 
growing cancer in the United States [21, 22].
The association between Hashimoto’s thyroiditis and thy-
roid cancer has been debated and remains an active area of 
research and controversy [20, 22–24]. If Hashimoto’s thy-
roiditis could be recognized as a precursor or a risk factor 
for thyroid cancer, this would have an obvious high clini-
cal impact in paediatric population, given that Hashimoto’s 
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thyroiditis is a rather common disease, with a rising inci-
dence worldwide [22].
Keskin et al. [20] analyzed 300 children with AIT and 
found the thyroid nodule rate on AIT ultrasound background 
to be 13%, and the thyroid malignancy rate 0.67%. Corrias 
et al. [9] reported a thyroid nodule prevalence of approxi-
mately 31.5% in 365 pediatric AIT patients; thyroid can-
cer was present in at least 3% of the patients and in 9.6% 
of a subset of patients with thyroid nodules. In accordance 
to these studies, in our work a nodular variant of AIT was 
found in 18.9% patients, PTC constituted 23.5% of nodular 
variant cases and in the whole group 4.5%. To summarize 
as shown above the incidence of PTC in AIT ranges from 
0.67 to 4.5% in children. However, as shown in our study, 
this prevalence of PTC is increased in nodular AIT vari-
ant with normoechogenic irregular parenchyma. Based on 
detailed ultrasound scans analysis, we are convinced that 
this AIT variant might represent a different type of disease 
or the parenchymal changes may be secondary to the pres-
ence of an occult PTC. The question arises then if in these 
patients AIT is not secondary to the cancer. Our results are 
in line with Paparodis findings that the form of AITD pathol-
ogy (destructive, clinically evident hypothyroid vs. a less 
destructive, nonclinically evident) might play a role in differ-
entiated thyroid cancer risk [25]. Patients with less destruc-
tive AITD (euthyroid, or with compensated hypothyroidism) 
were described to show a higher risk for differentiated thy-
roid cancer than were patients with a clear destructive AITD 
[25]. These observations together with our clinical US find-
ings in paediatric population could provide a support for the 
hypothesis that AIT might be a secondary event. Whether 
PTC develops despite autoimmunity (tumor immune-escape 
mechanism), or due to a target-specific immune response 
(inflammation, preexisting autoimmunity), or whether AIT 
develops because of cross-reacting antitumor immunity, 
needs further research especially in paediatric age range 
group [26].
From histopathological perspective, it is important to 
distinguish between diffuse lymphocytic infiltration and 
focal peritumoral lymphocytic thyroiditis [22]. Hashimoto’s 
thyroiditis is a diffuse lymphocytic infiltration; therefore, 
it is considered an independent chronic process and does 
not signify a reaction to the tumor [22, 26]. The reason for 
the induced antitumor immune response might be the exist-
ence of yet undiagnosed papillary thyroid microcarcinomas 
[26]. Possibly, these small malignancies that induce a locally 
defined antitumor immune response, followed by a locally 
defined inflammation that promotes cross-reactivity, induce 
an epitope-specific autoimmune response [26]. This hypoth-
esis certainly needs investigation in paediatric population.
The analysis of the thyroid status revealed that in our 
group 47.5% patients were hypothyroid (54.1% with com-
pensated and 45.9% with an overt hypothyroidism), 36.8% 
euthyroid and 15.6% hyperthyroid at diagnosis. In accord-
ance with other studies presenting that the majority of AIT 
children was euthyroid at diagnosis, 62.5% of patients in 
our group did not receive thyroxine treatment at diagnosis 
(euthyroid and compensated hypothyroid patients) [15, 17, 
27].
The ultrasound variant with diffuse thyroiditis and 
hypoechogenic background and normoechogenic paren-
chyma is also defined an atrophic form but the majority of 
children with this variant presents with goiter [15, 27]. In 
children, an atrophic form of this variant is not seen; how-
ever, we typically observe a reduction of a goiter with the 
treatment and with time. An atrophic form is usually seen 
in a transition period and in adulthood. 69.8% of patients 
with this variant in our group were hypothyroid and the 
levels of aTPO and aTG were significantly higher than 
in patients with other variants similarly to other studies 
[18]. A diffuse fibrosis of the gland in this variant can 
become evident at a later stage of the disease [15, 19]. 
Fine echogenic fibrous septae may produce a pseudolobu-
lated appearance of the parenchyma, however, as shown 
in our study a special notice must be given in differential 
diagnosis to a diffuse sclerosing variant of PTC present-
ing tiny disseminated hyperechogenic septae and multiple 
microcalcifications within the whole thyroid gland [19].
As expected and in accordance to other studies [18], 
abnormalities in thyroid status in AIT variants with dif-
fuse thyroiditis with hypoechogenic background and nor-
moechogenic parenchyma, with irregular background and 
with micronodulations were more intense than in nodular 
variant with normoechogenic parenchyma and in diffuse 
hypoechogenic background.
On the other hand, patients with nodular variant and 
normoechogenic irregular background had significantly 
lower TSH, aTPO and aTG levels than patients with most 
common AIT variant. The majority of patients with nodu-
lar variant as well as with PTC did not receive a thyroxine 
therapy at diagnosis. This might be in agreement with Pap-
arodis et al. [25] finding of a higher risk for differentiated 
thyroid cancer in patients with less destructive thyroiditis.
A limitation of the present study is a relatively small 
number of patients. Multi-center transition studies involv-
ing both paediatric and adult patients are needed to evalu-
ate disease and thyroid ultrasound data especially in the 
light of previous recommendations that thyroid US scans 
in children with AIT as not changing the treatment, clini-
cal course or outcome, should not be indicated routinely 
[27] and current recommendations to perform annual thy-
roid US check-up in all AIT patients [8] or only in patients 
with a suspicious thyroid examination (suspected nodule 
or significant gland asymmetry) especially if associated 
with palpable cervical lymphadenopathy [28].
379J Endocrinol Invest (2018) 41:371–380 
1 3
What our study adds is a proposal to place children with 
nodular variant and normoechogenic irregular background 
in the PTC development risk group. Additionally, presented 
ultrasound classification of AIT variants is relatively novel 
in paediatric population and represents good basis for further 
exploration of PTC susceptibility.
Conclusion
Patients with AIT and nodular variant with normoechogenic 
irregular background of the thyroid gland on US scans are 
in the risk group of developing PTC and should be followed 
up with regular neck US assessment.
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